US Patent Issued to Chongqing Genrix Biopharmaceutical on Feb. 24 for "BCMA x CD3 T bispecific cell engager" (Chinese Inventors)

ALEXANDRIA, Va., Feb. 24 -- United States Patent no. 12,559,556, issued on Feb. 24, was assigned to Chongqing Genrix Biopharmaceutical Co. Ltd. (Chongqing, China).

"BCMA x CD3 T bispecific cell engager" was invented by Zhigang Liu (Beijing), Shunan Wan (Beijing), Yulan Liu (Beijing), Xiaobo Hao (Beijing), Junjie Hu (Beijing) and Jingjing Guo (Beijing).

According to the abstract* released by the U.S. Patent & Trademark Office: "A bispecific antibody, which comprises an antigen-binding portion against human CD3E and an antigen-binding portion against human BCMA."

The patent was filed on June 27, 2025, under Application No. 19/252,926.

*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netac...